What is the brand name of pazopanib/pazopanib? How to get

The original trade name of Pazopanib/Pazopanib is VOTRIENT, and its Chinese trade name is Weiqant. It is developed by Novartis, an internationally renowned pharmaceutical company. This drug is mainly approved for the treatment of advanced renal cell carcinoma and specific types of soft tissue sarcoma, and has been included in the regular treatment system by drug regulatory agencies in many countries and regions around the world. In mainland China, Vitant has been approved for marketing by the National Medical Products Administration (NMPA) and has been successfully included in the medical insurance directory, reducing the financial burden on patients.

The most common specifications of pazopanib on the market are200mg or 400mg tablets, each bottle contains 30 tablets. Doctors usually determine the initial dose based on the patient's condition and physical condition, and adjust the dose based on adverse reactions that occur during treatment. Victant is a prescription drug and can only be purchased with a doctor's prescription through hospital oncology departments or designated pharmacies. With the support of medical insurance, patients who meet the indications and have advanced renal cell carcinoma and meet first-line treatment standards can enjoy a certain proportion of medical insurance reimbursement, which lowers the threshold for medication.

In addition to original drugs, there are also legal versions of generic drugs for sale in some overseas markets such as India and Bangladesh. The ingredients of these generic drugs are basically the same as those of the original drugs, and the prices are relatively more affordable. They are especially suitable for self-paying patients or groups who cannot afford the high cost of original drugs. Some domestic patients obtain these generic drugs through cross-border medical platforms and international drug procurement channels. For example, pharmaceutical factories in India and Bangladesh have mature generic versions. However, it should be noted that generic drugs have not yet been approved for marketing in China, and they may need to be purchased on the basis of medical consultation to avoid purchasing fake or inferior drugs through informal channels.

Reference materials:https://www.votrient.com/